Clinical trial
Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
NCT03023527 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
- Lead sponsor
- PETHEMA Foundation
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- January 31, 2017
- Completion date
- January 31, 2018
- Enrollment
- 6 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.